ProQR Therapeutics (PRQR) Debt Ratio (2013 - 2026)

ProQR Therapeutics (PRQR) posted Debt Ratio of 0.05 for Q1 2026, up 15.56% sequentially from 0.04 in Q4 2025, and up 62.71% YoY from 0.03 in Q1 2025.

ProQR Therapeutics (PRQR) Debt Ratio (2013 - 2026) Analysis & Trends

ProQR Therapeutics has reported Debt Ratio for 14 years, with the latest figure at 0.05 in Q1 2026.

Quarterly Debt Ratio rose 62.71% year-over-year to 0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.05 (up 62.71% YoY) and the FY2025 annual result came in at 0.04, up 58.38% from the prior year.
Debt Ratio rose to 0.05 in Q1 2026 per PRQR's latest filing, from 0.04 in the prior quarter.
Over five years, Debt Ratio peaked at 0.42 in Q2 2022 and troughed at 0.03 in Q4 2024.
A 5-year average of 0.09 and a median of 0.04 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2023: Debt Ratio jumped 223876963.54% in 2022, then tumbled 88.55% in 2023.
Over 5 years, Debt Ratio stood at 0.04 in 2022, then declined by 21.24% to 0.03 in 2023, then slipped by 12.36% to 0.03 in 2024, then soared by 58.38% to 0.04 in 2025, then increased by 15.56% to 0.05 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.05, 0.04, and 0.04 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	ProQR Therapeutics	206.80 Mn	111.86 Mn	-	0.05

Download Data